Gender-Specific Phase III Trial For Advanced Non-Small Cell Lung Cancer Approved

Armen Hareyan's picture

Non-Small Cell Lung Cancer


Cell Therapeutics has begun a confirmatory phase III clinical trial of combination chemotherapy for women with advanced non-small cell lung cancer (NSCLC) -- the most lethal cancer facing women today.

The trial, known as PGT307, will focus exclusively on women with pre-menopausal estrogen levels -- a group whose survival is significantly shorter than post-menopausal women. XYOTAX

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.